Gufic Biosciences gets DCGI nod for Thymosin Alpha-1

05 Apr 2022 Evaluate

Gufic Biosciences has received DCGI approval for Thymosin Alpha-1 (Immunocin - A Brand of Gufic for the said drug) as an add-on therapy for the treatment of moderate-to-severe COVID-19 patients requiring ventilator support (NIV as well as Mechanical Ventilation). Immunocin, an Immuno-modulator drug, significantly reduced the risk of death in the Phase 3 Clinical trial in adult patients with moderate-to-severe COVID-19.

Gufic Biosciences is engaged in diversified business viz. Pharma, Healthcare, Bio- Technology, Seeds, Herbal etc.

Gufic Biosciences Share Price

403.15 -4.70 (-1.15%)
22-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1797.80
Dr. Reddys Lab 1213.90
Cipla 1486.30
Lupin 2069.95
Zydus Lifesciences 948.70
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.